国药股份: 北京国枫律师事务所关于国药集团药业股份有限公司2025年第一次临时股东大会的法律意见书

Core Points - The legal opinion letter issued by Beijing Guofeng Law Firm confirms the legality of the convening, holding procedures, and voting results of the 2025 first extraordinary general meeting of China National Pharmaceutical Group Corporation [1][5] - The meeting was convened by the company's board of directors and followed the required legal and regulatory procedures [3][4] - A total of 216 shareholders participated in the meeting, representing 469,127,246 shares, which accounts for 62.1769% of the total voting shares [4] Meeting Procedures - The meeting was called by the company's board of directors and publicly announced on June 21, 2025, through various media outlets [2][3] - The meeting was held on July 7, 2025, using a combination of on-site and online voting methods [3][4] - The procedures for convening and holding the meeting were found to be in compliance with relevant laws, regulations, and the company's articles of association [3][5] Voting Results - The meeting included the election of directors, with the proposal receiving 468,617,214 votes in favor, representing a significant majority of the voting shares [5] - The voting process was conducted in accordance with legal requirements, and the results were verified by appointed representatives [5] - The legal opinion confirms that the voting procedures and results are valid and comply with all applicable regulations [5]